

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**Form 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of September 2018  
Commission File Number 001-37846

---

**CELLECT BIOTECHNOLOGY LTD.**

(Translation of registrant's name into English)

---

**23 Hata'as Street**

**Kfar Saba, Israel 44425**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):

---

On September 5, 2018, Collect Biotechnology Ltd. (the “Company”) determined to withdraw the sole proposal to elect an external director at the Company’s Extraordinary Meeting of Shareholders, which was scheduled to be held on September 6, 2018, due to a conflict of interest that disqualified the candidate from serving as an external director. Accordingly, the Extraordinary Meeting of Shareholders has been cancelled. The Company intends to propose a new candidate for election as an external director and to convene a shareholders’ meeting to approve such candidate at the earliest opportunity.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Cellect Biotechnology Ltd.

By: /s/ Eyal Leibovitz  
Name: Eyal Leibovitz  
Title: Chief Financial Officer

Date: September 5, 2018

---